📰 Beigene News
Page 3 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
December 18, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,200,000 shares, a decline of 18.9% from the November 15th total of 1,480,000 shares. Based on an average daily volume of 213,500 shares, the short-interest ratio is presently 5.6 days. […]
December 10, 2023
Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation BTK inhibitor.
December 5, 2023
China, U.S. combined account for approximately 40% of cancer deaths worldwide annually
December 3, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,480,000 shares, an increase of 23.3% from the October 31st total of 1,200,000 shares. Based on an average trading volume of 213,200 shares, the short-interest ratio is […]
November 22, 2023
BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.
November 12, 2023
StockNews.com upgraded shares of BeiGene (NASDAQ:BGNE – Free Report) from a sell rating to a hold rating in a research report released on Thursday. Other equities research analysts have also issued reports about the stock. Citigroup dropped their price objective on shares of BeiGene from $290.00 to $285.00 and set a buy rating on the […]
November 10, 2023
Unveiling Financial Growth and Market Challenges
October 31, 2023
BeiGene Expands Presence in Middle East and North Africa Region with Opening of United Arab Emirates Office
October 30, 2023
BeiGene (NASDAQ:BGNE – Free Report) had its target price reduced by Citigroup from $290.00 to $285.00 in a research report released on Thursday, Benzinga reports. They currently have a buy rating on the stock. BGNE has been the subject of several other reports. Royal Bank of Canada started coverage on BeiGene in a report on […]
October 30, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) shares were up 11.2% during trading on Monday . The stock traded as high as $189.49 and last traded at $189.49. Approximately 49,345 shares traded hands during trading, a decline of 78% from the average daily volume of 221,350 shares. The stock had previously closed at $170.45. Analyst […]